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Dual action of L-Lactate on the 
activity of NR2B-containing NMDA 
receptors: from potentiation to 
neuroprotection
P. Jourdain1,2, K. Rothenfusser1,2, C. Ben-Adiba2, I. Allaman  1, P. Marquet2,3,4,5 & 
P. J. Magistretti1,2,6
L-Lactate is a positive modulator of NMDAR-mediated signaling resulting in plasticity gene induction 
and memory consolidation. However, L-Lactate is also able to protect neurons against excito-toxic 
NMDAR activity, an indication of a mitigating action of L-Lactate on NMDA signaling. In this study, 
we provide experimental evidence that resolves this apparent paradox. Transient co-application 
of glutamate/glycine (1 μM/100 μM; 2 min) in primary cultures of mouse cortical neurons triggers a 
NMDA-dependent Ca2+ signal positively modulated by L-Lactate (10 mM) or DTT (1 mM) but decreased 
by Pyruvate (10 mM). This L-Lactate and DTT-induced potentiation is blocked by Ifenprodil (2 μM), a 
specific blocker of NMDARs containing NR2B sub-units. In contrast, co-application of glutamate/glycine 
(1 mM/100 μM; 2 min) elicits a NMDAR-dependent excitotoxic death in 49% of neurons. L-Lactate 
and Pyruvate significantly reduce this rate of cell death processes (respectively to 23% and 9%) while 
DTT has no effect (54% of neuronal death). This L-Lactate-induced neuroprotection is blocked by 
carbenoxolone and glibenclamide, respectively blockers of pannexins and KATP. In conclusion, our 
results show that L-Lactate is involved in two distinct and independent pathways defined as NMDAR-
mediated potentiation pathway (or NADH pathway) and a neuroprotective pathway (or Pyruvate/ATP 
pathway), the prevalence of each one depending on the strength of the glutamatergic stimulus.
NMDA receptors (NMDARs) are glutamate-gated cation channels with high calcium permeability. They are 
involved in several aspects of brain activity such as neuronal development and neuroplasticity during learning 
and memory formation1. However, an overstimulation of NMDARs leads to neuronal damage (excitotoxicity), as 
illustrated by a variety of neurological disorders and pathological conditions2 such as ischemic brain injury and 
chronic neurodegenerative diseases such as Alzheimer’s disease or Amyotrophic Lateral Sclerosis3,4. NMDARs 
require two distinct molecules to be active: glutamate as the main agonist and a co-agonist, either glycine or 
D-Serine. Other endogenous substances found in the central nervous system can also act as potent modulators 
of NMDAR activity, for example protons, Zn2+, polyamines5 or L-Lactate6. The latter molecule has long been 
considered as a waste product of Glucose metabolism with no specific functions. This view of L-Lactate has 
however changed during the past three decades from waste product to fuel for neurons through the concept of 
the Astrocyte-Neuron Lactate Shuttle7,8 where astrocyte-derived L-Lactate acts as an energy substrate to meet 
the increased energy demands of neurons during neuronal activity. Furthermore, in addition to its role in energy 
metabolism, L-Lactate also acts as a signaling molecule for neuronal plasticity and Long-Term Memory for-
mation9,10 and for neuroprotection11–14. These two sets of properties of L-Lactate, namely neuroplasticity and 
neuroprotection (for review see15), may appear at first analysis contradictory. Indeed the positive modulation of 
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NMDARs by L-Lactate6 associated with neuroplasticity seems hard to reconcile with the neuroprotective action 
of L-Lactate against NMDAR-mediated excito-toxicity14. This apparent discrepancy is particularly reinforced by 
the fact that the positive modulation of NMDAR activity by L-Lactate is associated with an increase in the redox 
potential of neurons as determined by the NADH/NAD+ ratio6. Such redox conditions are known to increase the 
activity of NMDARs16,17 to a point where they may cause glutamate-evoked neurotoxicity18.
To address this apparent paradox, we performed a series of Ca2+ imaging studies using Fura-2 to measure 
[Ca2+]i elevations in cultured neurons before, during and after glutamate stimulation at concentrations of gluta-
mate ranging from 1 μM to 1 mM. Results reported in this article demonstrate that L-Lactate exerts two distinct 
effects on neuronal [Ca2+]i depending on the concentration of glutamate: potentiation of low (1 μM, subthresh-
old) and mitigation of elevated (1 mM, excito-toxic) concentrations of glutamate respectively. The potentiation 
by L-Lactate on NMDAR signaling in the presence of low glutamate concentrations involves the formation of 
NADH and modulation of the NR2B subunit. The mitigation of the [Ca2+]i increases elicited by excito-toxic con-
centrations of glutamate, are shared by Pyruvate and involve the formation of ATP, consistent with the previously 
described neuroprotective effect of L-Lactate and Pyruvate14.
Results
In this study, all Ca2+-responses induced by different concentrations of glutamate co-applied with a fixed and 
saturating concentration of glycine (100 μM) are recorded from cultured neurons aged to 17–22 DIV.
Co-application of glutamate and glycine evokes a Ca2+ signal associated with activation of 
NMDARs through a NR2B independent pathway. NMDARs are highly permeable to Ca2+; their acti-
vation requires the simultaneous presence glutamate and glycine19,20. In a first series of experiments, we applied 
a low concentration of glutamate (1 μM) corresponding to the resting concentration of glutamate in extracellular 
space21 in conjunction with glycine (100 μM). As shown in Fig. 1A, co-application of glutamate/glycine during 
2 min triggers a Ca2+ signal with a mean amplitude of 0.39 ± 0.07 a.u. (ncult = 9; ncells = 275). When the same glu-
tamate/glycine cocktail is applied to the same cultures after a minimum delay of 20 min, a second Ca2+ response 
of 0.36 ± 0.06 a.u. is observed, an amplitude which is not significantly different from the first one (p > 0.05; 
Fig. 1A and Table 1). To confirm that this excitatory stimulus activates NMDARs, MK801, a specific antago-
nist of NMDARs was used. In the presence of MK801 (40 μM), the [Ca2+]i elevation normally induced by the 
co-application of glutamate/glycine is totally blocked with a Ca2+ peak amplitude of 0.37 ± 0.06 a.u. in control 
condition vs 0.04 ± 0.01 a.u. with MK801 (p < 0.005; ncult = 8; ncells = 271) (Fig. 1B and Table 1).
NMDARs are a heteromeric complexes composed of the NR1 and at least one of the NR2 sub-units. The 
NR2 sub-units, in particular NR2A and NR2B, two sub-units expressed in primary cortical neuronal cultures, 
strongly influence the kinetics and pharmacological properties of NMDARs22. To differentiate the involvement 
of either NR2A or NR2B, we used Ifenprodil, a specific blocker of NR2B-containing NMDARs. Bath application 
of Ifenprodil (2 μM), did not affect the Ca2+ responses evoked by the glutamate/glycine application (control: 
0.33 ± 0.06 a.u.; Ifenprodil: 0.28 ± 0.06 a.u.; ncult = 7; ncells = 299) (Fig. 1B and Table 1). This observation indi-
cates that the glutamate/glycine-induced Ca2+ signals in control condition does not involve NR2B-containing 
NMDARs.
L-Lactate specifically potentiates the Ca2+ signal evoked by the co-application of glutamate 
and glycine through activation of NR2B-containing NMDARs. In the presence of L-Lactate 
(10 mM), the Ca2+ response induced by glutamate/glycine (1 μM/100 μM; 2 min) is significantly increased with a 
Ca2+ peak amplitude rising from 0.33 ± 0.05 a.u. in control to 0.50 ± 0.05 a.u. in L-Lactate condition (p < 0.005; 
ncult = 11; ncells = 468) (Fig. 2A,C and Table 1). This effect depends upon NMDAR activation since direct NMDAR 
activation by the selective agonist NMDA (by co-application NMDA (30 μM) and Glycine (100 μM) during 2 min) 
is also significantly potentiated by L-Lactate (Ca2+ peak amplitude rising from 0.34 ± 0.04 a.u. to 0.42 ± 0.04; 
ncult = 9; ncells = 340, p < 0.05) (Fig. 2A,C and Table 1). Moreover, in the presence of Ifenprodil (2 μM), a selective 
blocker of the NR2B subunit of NMDARs, in the bath medium, L-Lactate (10 mM) no longer potentiates the Ca2+ 
response triggered by glutamate/glycine which is identical to the one obtained in control condition (Fig. 2A,C 
and Table 1). Finally, when glycine was substituted by D-serine, another endogenous co-agonist of the NMDARs, 
L-Lactate also slightly increased the Ca2+ signal evoked by the cocktail glutamate/D-serine (1 μM/100 μM; 2 min) 
from 0.33 +/0.07 a.u. to 0.45 ± 0.06 a.u. (ncult = 9; ncells = 317); this increase was however not statistically signifi-
cant (Fig. 2A,C and Table 1). Since D-serine preferentially acts on NR2A-containing NMDARs while glycine pref-
erentially acts on NR2B-containing NMDARs23, this set of experiments further stresses that L-Lactate modulates 
NR2B-containing NMDARs.
Concerning the specificity of L-Lactate, the use of two of its analogues, Pyruvate and D-Lactate at 10 mM did 
not increase the Ca2+ signal evoked by the cocktail of glutamate/glycine (Fig. 2B). In fact, both molecules signif-
icantly decreased the Ca2+ responses by 52% (p < 0.05) and 51% (p < 0.05) respectively (Fig. 2B,C and Table 1), 
further stressing the specificity of L-Lactate in the potentiating the Ca2+ signal induced by the co-application 
of glutamate/glycine. In addition, when 10 mM L-Lactate was substituted with an equicaloric concentration of 
Glucose (5 mM extra Glucose ACSF), the Ca2+ signal evoked by the cocktail of glutamate/glycine is significantly 
decreased (control: 0.29 ± 0.04 a.u.; 5 mM extra Glucose: 0.14 ± 0.06 a.u.; ncult = 8; ncells = 425; p < 0.05), in a man-
ner similar to that observed in the presence of Pyruvate (Fig. 2B,C and Table 1). This observation stresses again 
the specificity of L-Lactate for potentiation of NMDAR activity over other energy substrates.
The L-Lactate-induced potentiation is dependent on the redox state of the cell. It has been 
shown that NMDARs express regulatory redox sites, the reduced state of them favoring NMDAR activity16,17. The 
metabolism of L-Lactate to Pyruvate by L-Lactate Dehydrogenase (LDH) results in the intracellular production of 
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NADH, an endogenous reducing molecule. Consistently, in our cultures, exposure of neurons to ACSF containing 
L-Lactate (10 mM) significantly increases the intracellular NADH/NAD+ ratio by 68% (Control: 6.49 +/− 0.65; 
ncult = 12; Lactate: 10.95 +/− 1.56; ncult = 12; p < 0.005) (Table 2). This result is in agreement with the study of 
Yang et al.6 where they demonstrate that L-Lactate (but not Pyruvate) increases this intracellular NADH/NAD+ 
ratio in cultured neurons. We also tested Glucose as a possible source for the increase of the intracellular NADH/
NAD+ ratio24. In the presence of 5 mM extra Glucose ACSF, the intracellular NADH/NAD+ ratio is significantly 
decreased by 29% (5 mM extra Glucose: 4.63 +/− 0.64; ncult = 11; p < 0.05) (Table 2) confirming the specificity of 
L-Lactate to be the main source of production for cytosolic NADH, the endogenous reducing agent.
Previous evidence has been provided showing that L-Lactate promotes plasticity gene expression by potenti-
ating NMDAR signaling in neurons through a similar mechanism associated with changes in intracellular redox 
state6. Based on the foregoing we used DTT, a reducing agent, to test the possibility that the L-Lactate-induced 
potentiation of NMDAR activity is also associated with some changes in the redox state of the cell. In the pres-
ence of DTT (1 mM) the Ca2+ signal induced by the co-application of glutamate/glycine (1 μM/100 μM; 2 min) 
is strongly increased from 0.31 ± 0.04 a.u. in control to 0.52 ± 0.08 a.u. in DTT condition (p < 0.05; ncult = 9; 
Figure 1. Co-application of glutamate and glycine evokes a Ca2+ signal associated with activation of NMDARs 
through an NR2B independent pathway. (A1–3) Typical fluorescence images of cortical neurons labelled with 
Fura-2 (380 nm excitation) (Scale Bar: 100 μm; A1). Intracellular calcium signals (grey – 27 individual and 
black – average calcium traces recorded from cultured neurons in A1) following 2 successive co-applications of 
glutamate and glycine (2 min; dots; A2). Calcium traces indicate that there is no detectable difference between 
the 2 successive Ca2+ responses evoked by the co-application of glutamate/glycine. Bar charts comparing 
the amplitude for Ca2+ responses evoked by 2 successive co-application of glutamate/glycine (ncult = 9; 
ncells = 275; A3). (B1–3) Intracellular Ca2+ signals (black–average calcium traces recorded from 19 neurons in B1 
and 37 neurons in B2) following 2 successive applications of glutamate/glycine (2 min; dots) in control condition 
(1st application) and in presence of the broad-spectrum NMDAR antagonist MK801 (40 μM; B1) or a specific 
blocker of the NR2B sub-unit Ifenprodil (2 μM; B2). The 2nd Ca2+ response induced by the co-application 
of glutamate/glycine is totally blocked by MK801 (B1) but not by Ifenprodil (B2). Bar chart summarizing 
the significant inhibitory effect of MK801 (ncult = 8; ncells = 271) and the lack of effect of Ifenprodil (ncult = 7; 
ncells = 299) on Ca2+ responses evoked by the co-application of glutamate/glycine (B3). Results are presented as 
means ± SEM (***p < 0.005; paired t-test).
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ncells = 343) (Fig. 3A and Table 1). Moreover, in the presence of Ifenprodil (2 μM), DTT does not potentiate the 
Ca2+ response triggered by the glutamate/glycine cocktail (control: 0.37 ± 0.06 a.u.; DTT+ Ifenprodil: 0.33 ± 0.05 
a.u.; ncult = 8; ncells = 301) (Fig. 3B and Table 1), this result reinforcing the notion of a similarity between the 
mechanism of action of L-Lactate and this reducing agent. Consistently, when L-Lactate is perfused in the pres-
ence of DTNB (200 μM), an oxidizing agent, the potentiation induced by L-Lactate on the Ca2+ response (con-
trol: 0.34 ± 0.06 a.u.; L-Lact. + DTNB: 0.32 ± 0.06 a.u.; ncult = 8; ncells = 407) is no longer observed (Fig. 3C and 
Table 1).
Finally, Stiripentol (200 μM), a blocker of Lactate Dehydrogenase (LDH) which prevents the metabolism of 
L-Lactate to Pyruvate and consequently the formation of NADH, also blocks the L-Lactate-induced potentiation 
(control: 0.31 ± 0.06 a.u.; L-Lact. + Stiripentol: 0.26 ± 0.05 a.u.; ncult = 9; ncells = 298) (Fig. 3D and Table 1), further 
stressing the fact that redox state changes evoked by L-Lactate through NADH production by LDH are essential 
for the potentiation of NMDAR activity.
Blockade of the intracellular Ryanodine Receptor (RyR) impacts the maintenance of Ca2+ signal 
during L-Lactate-induced potentiation. Obtained Results clearly indicate that the L-Lactate-induced 
potentiation is characterized not only by an increase in the Ca2+ peak amplitude but also by a longer peak dura-
tion (control: 551 ± 53 s; L-Lact.: 850 ± 114 s; ncult = 11; ncells = 468; p < 0.05) (Fig. 4A,C). We sought to determine 




(test) % of effect
Paired t-Test (2nd appl. 
vs 1st appl.)
Control
(ncult = 9; ncells = 275)
0.39 ± 0.07 0.36 ± 0.06 91.7 +−/ 14.8 n.s
MK801 (40 μM)
(ncult = 8; ncells = 271)
0.37 ± 0.06 0.04 ± 0.01 9.4 ± 2.7 <0.005
Ifenprodil (20 μM)
(ncult = 7; ncells = 299)
0.33 ± 0.07 0.28 ± 0.06 84.8 ± 17.3 n.s
L-Lactate (2 mM)
(ncult = 9; ncells = 376)
0.32 ± 0.03 0.35 ± 0.04 110.2 ± 11.8 n.s
L-Lactate (5 mM)
(ncult = 10; ncells = 365)
0.35 ± 0.06 0.34 ± 0.07 95.4 ± 14.8 n.s
L-Lactate (10 mM)
(ncult = 11; ncells = 468)
0.33 ± 0.05 0.50 ± 0.05 152.8 ± 11.4 <0.005
Pyruvate (10 mM)
(ncult = 9; ncells = 317)
0.37 ± 0.08 0.19 ± 0.09 51.6 ± 19.2 <0.05
D-Lactate (10 mM)
(ncult = 9; ncells = 326)
0.37 ± 0.07 0.19 ± 0.07 50.7 ± 17.6 <0.05
5 mM extra Glucose
(ncult = 8; ncells = 425)
0.29 ± 0.04 0.14 ± 0.06 47.2 ± 19.6 <0.05
L-Lactate (10 mM) + Ifenprodil
(40 μM) (ncult = 8; ncells = 315)
0.35 ± 0.07 0.34 ± 0.04 96.4 ± 11.4 n.s
L-Lactate (with NMDA 30 μM + glycine
100 μM) (ncult = 9; ncells = 340)
0.34 ± 0.04 0.42 ± 0.04 122.6 ± 9.2 <0.05
L-Lactate (with D-Serine 100 μM)
(ncult = 9; ncells = 317)
0.33 ± 0.07 0.45 ± 0.06 137.4 ± 18.9 n.s
DTT (1 mM)
(ncult = 9; ncells = 343)
0.31 ± 0.04 0.52 ± 0.08 169.3 ± 23.2 <0.05
L-Lactate (10 mM) + DTNB (200 μM) (ncult = 8; ncells = 407) 0.34 ± 0.06 0.32 ± 0.06 92.7 ± 16.2 n.s
L-Lactate (10 mM) + Stiripentol
(200 μM) (ncult = 9; ncells = 298)
0.31 ± 0.06 0.26 ± 0.05 82.5 ± 12.9 n.s
DTT (1 mM) + Ifenprodil (2 μM)
(ncult = 8; ncells = 301)
0.37 ± 0.06 0.33 ± 0.05 89.4 ± 14.3 n.s
Lactate (10 mM) + Ryanodine (10 μM)
(ncult = 7; ncells = 331)
0.32 ± 0.01 0.41 ± 0.03 129.6 ± 10.1 <0.05




(test) % of effect
Paired t-Test (1st appl. 
vs 2nd appl.)
Ifenprodil (2 μM)
(ncult = 6; ncells = 187)
0.52 ± 0.06 0.32 ± 0.06 61.3 ± 10.8 <0.005
L-Lactate (10 mM)
(ncult = 6; ncells = 276)
0.49 ± 0.02 0.51 ± 0.03 103 ± 5.3 n.s




(test) % of effect
Paired t-Test (1st appl. 
vs 2nd appl.)
Ifenprodil (2 μM)
(ncult = 6; ncells = 138)
0.59 ± 0.08 0.42 ± 0.09 71.4 ± 15.7 <0.005
L-Lactate (10 mM)
(ncult = 6; ncells = 155)
0.55 ± 0.05 0.49 ± 0.07 88.2 ± 12 n.s
Table 1. Summary of the Ca2+ peak amplitude induced by 2 successive applications of glutamate/glycine in 
different conditions. Values are means ± SEM. Statistics data correspond to a Paired Student’s t-test (n.s: non 
significant, p > 0.05).
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whether the opening of NR2B-containing NMDARs alone could explain such an increase in Ca2+ response dura-
tion in L-Lactate condition or whether other activation cascades intervene in the generation of this Ca2+ sig-
nal. Thus, we investigated a possible involvement of Ca2+-induced Ca2+ release mediated by intracellular RyRs. 
Indeed, such an intracellular release of Ca2+ is: (1) a mechanism that can contribute to the amplification of the 
Ca2+ influx generated by NMDAR activation25,26 and (2) is known to be redox sensitive27,28. To this end, neu-
ronal cultures were pre-treated with ryanodine at 100 μM to irreversibly block the intracellular RyR29. In these 
conditions, the L-Lactate-induced potentiation persists with a significant increase of Ca2+ peak amplitude of 
30% (control: 0.32 ± 0.01 a.u.; L-Lact.: 0.41 ± 0.03 a.u.; p < 0.05; ncult = 7; ncells = 331) (Fig. 4B,C and Table 1). 
However, when cultures were pre-treated with ryanodine, the duration of the Ca2+ response is not significantly 
modified by L-Lactate (control: 487 ± 62 s; L-Lact.: 547 ± 69 s; ncult = 7; ncells = 331; p > 0.05) (Fig. 4B,C). This 
Figure 2. L-Lactate specifically potentiates the Ca2+ signal evoked by the glutamate/glycine cocktail through 
activation of NR2B-containing NMDARs: an effect associated to an increase of the intracellular NADH/NAD 
ratio. (A1–4) Intracellular Ca2+ signals (average Fura-2 ratio) recorded from 4 different cultures (A1: ncell = 37; A2: 
ncell = 35; A3: ncell = 27; A4: ncell = 50) and following 2 successive co-applications of glutamate/glycine (2 min; dots; 
A1 and A3), NMDA/glycine (2 min; dots; A2) and glutamate/D-Serine (2 min; dots; A3) in presence of L-Lactate 
alone (10 mM; A1,A2 and A4) or L-Lactate + Ifenprodil (2 μM; A3) for the 2nd co-application. Regardless to the 
configuration, calcium traces clearly indicate that L-Lactate induces potentiation of the Ca2+ responses for the co-
application of glutamate/glycine (A1) or NMDA/glycine (A2) this L-Lactate-induced potentiation being blocked 
by Ifenprodil (A3) and lacking when glycine is substituted by D-Serine (A4). (B1–3) Intracellular calcium signals 
(average Fura-2 ratio) following 2 successive co-applications of glutamate/glycine (2 min; dots) and recorded 
from 3 different cultures in presence of Pyruvate (10 mM) (ncell = 20; B1), D-Lactate (10 mM) (ncell = 55; B2) or 
Glucose (5 mM extra Glucose ACSF) (ncell = 62; B2). The Ca2+ traces show clearly that neither Pyruvate (B1) nor 
D-Lactate (B2) are able to potentiate the Ca2+ response evoked by the co-application of glutamate/glycine.  
(C) Bar charts summarizing the significant potentiating effects of L-Lactate on Ca2+ responses evoked by the 
co-application of glutamate/glycine (ncult = 11; ncells = 468) or NMDA/glycine (ncult = 9; ncells = 343). In contrast, 
see the lack of L-Lactate-induced potentiation in presence of Ifenprodil (ncult = 8; ncells = 315) or when glycine 
is substituted by D-Serine (ncult = 9; ncells = 317). Finally, Pyruvate (ncult = 9; ncells = 317), D-Lactate (ncult = 9; 
ncells = 326) or Glucose (ncult = 8; ncells = 425) significantly decrease the Ca2+ signal. Results are presented as 
means ± SEM (*p < 0.05; ***p < 0.005; paired t-test).
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set of experiments suggests that the L-Lactate-induced potentiation is mainly due to a change of redox state of 
NR2B-containing NMDARs, resulting in Ca2+ influx which, in turn, can activate RyRs to amplify the Ca2+ signal.
The increase of glutamate concentration triggers an NR2B component in the Ca2+ signal while 
L-Lactate-induced potentiation disappears. The experiments reported so far were carried out in the 
presence of a low concentration of glutamate (1 μM), and of glycine (100 μM). Considering that the concentra-
tion of glutamate can reach values anywhere from 30 μM up to over 1 mM in the synaptic cleft during neuronal 
activation21, we decided to determine if the L-Lactate-induced potentiation persisted at higher concentrations of 
glutamate. When applying 2 successive co-applications of glutamate/glycine (10 μM/100 μM; 2 min) according 
to the same protocol, we observed no difference between the two evoked Ca2+ signals in control and L-Lactate 
conditions with respectively 0.49 ± 0.02 a.u. and 0.51 ± 0.03 a.u. for the Ca2+ peak amplitude (ncult = 6; ncells = 276) 
(Fig. 5A and Table 1). Similarly, with a glutamate/glycine cocktail of 100 μM/100 μM (2 min), the two evoked Ca2+ 
signals in control and L-Lactate conditions are of the same order (control: 0.55 ± 0.05 a.u.; L-Lact: 0.49 ± 0.07 a.u.; 
ncult = 6; ncells = 155) (Fig. 5A and Table 1), indicating that L-Lactate is unable to potentiate the NMDAR activity 
at high concentrations of glutamate.
Figure 3. L-Lactate-induced potentiation depends on the redox state of the cell. (A1,B1,C1 and D1) Intracellular 
Ca2+ signals (average Fura-2 ratio) following 2 successive co-applications of glutamate/glycine (2 min; dots) 
and recorded from 4 different cultures in presence of DTT (1 mM) (ncell = 43; A1), DTT (1 mM) + Ifenprodil 
(2 μM) (ncell = 21; B1), L-Lactate (10 mM) + DTNB (200 μM) (ncell = 62; C1) or L-Lactate (10 mM) + Stiripentol 
(200 μM) (ncell = 42; D1). Only the reducing agent DTT alone potentiates the Ca2+ response evoked by the co-
application of glutamate/glycine (A1). (A2,B2,C2 and D2) Bar charts summarizing the significant potentiating 
effect of DTT (ncult = 9; ncells = 343; A2) blocked by Ifenprodil (ncult = 8; ncells = 301; B2) and the blockade of 
the L-Lactate-induced potentiation in presence of DTNB (ncult = 8; ncells = 407; C2) or Stiripentol (ncult = 9; 
ncells = 298; D2) on the Ca2+ signal triggered by co-application of glutamate/glycine. Results are presented as 
means ± SEM (*p < 0.05; paired t-test).
Condition NADH/NAD+ ratio One-Way Anova
Control (ncult = 12) 6.49 +/− 0.65
L-Lactate (10 mM) (ncult = 12) 10.95 +/− 1.56 <0.005
5 mM extra Glucose (ncult = 11) 4.63 +/− 0.64 <0.05
Table 2. Summary of intracellular NADH/NAD+ ratio measured in different conditions. Values are 
means ± SEM. Statistics data correspond to a Dunnett’s post hoc test following a one-way ANOVA.
www.nature.com/scientificreports/
7SCIEntIfIC REPORtS |  (2018) 8:13472  | DOI:10.1038/s41598-018-31534-y
Interestingly, we have previously observed that a low concentration of glutamate (1 μM), even in association to 
glycine, was unable to activate NR2B-containing NMDARs, except in the presence of L-Lactate. The fact that the 
L-Lactate-induced potentiation disappears in the presence of higher glutamate concentrations (always in pres-
ence of glycine), suggests that NR2B-containing NMDARs are already stimulated by higher glutamate concentra-
tions, making the action of L-Lactate ineffective. To address this question, we used Ifenprodil in the presence of 
the above mentioned higher concentrations of glutamate. As shown in Fig. 5B, the Ca2+ signal evoked by 10 μM 
glutamate in the presence of 100 μM glycine (2 min) is strongly and significantly reduced by Ifenprodil (2 μM) 
(control: 0.52 ± 0.06 a.u.; Ifenprodil: 0.32 ± 0.06 a.u.; p < 0.005; ncult = 6; ncells = 187) (Table 1). The same type of 
antagonism by Ifenprodil is observed for a co-application of glutamate/glycine (100 μM/100 μM): the amplitude 
of the Ca2+ response triggered by glutamate/glycine is 0.59 ± 0.08 a.u. in control condition and 0.42 ± 0.09 a.u. 
with Ifenprodil (ncult = 6; ncells = 138) (Fig. 5B and Table 1).
This set of results indicates that in the presence of high concentrations of glutamate (+glycine), 
NR2B-containing NMDARs are stimulated, and that L-Lactate renders low concentrations of glutamate effec-
tive through these same NR2B-containing NMDARs.
L-Lactate decreases the rate of cell death triggered by pathological concentrations of gluta-
mate: involvement of the Pyruvate/ATP pathway. It is well established that an excessive concen-
tration of glutamate overstimulates NMDARs triggering several downstream neurotoxic cascades caused by an 
intracellular Ca2+ overload30. As expected, a co-application of glutamate/glycine (1 mM/100 μM; 2 min) trig-
gers strong Ca2+ signals with an amplitude of 0.87 ± 0.14 a.u. (ncult = 7; ncells = 263) that entails two components 
(Fig. 6A and Table 3): 1/ a reversible response corresponding to a Ca2+ peak followed by a complete or incom-
plete recovery; 2/ an irreversible response corresponding to a sustained plateau of the Ca2+ signal. These two 
Ca2+ responses were observed in 135 out of 263 cells (around 51%) and 128 out of 263 cells (around 49%), 
respectively. Concomitantly to the Ca2+ overload, it has been shown that glutamate-induced excito-toxicity trig-
gers a rapid and acute swelling of cell bodies due to Na+, Cl− and water inflows31,32. Accordingly, by using a 
Figure 4. The RyRs blockade impacts only the maintenance of Ca2+ signal during L-Lactate-induced 
potentiation. (A1,B1) Averaged Ca2+ traces recorded from 65 neurons (A1) and 49 neurons (B1) following 2 
successive applications of glutamate/glycine (2 min; dots) in control and in presence of L-Lactate (10 mM), 
the neurons in B1 coming from a culture pre-treated with ryanodine (100 μM). (A2,B2) The scaling of evoked 
Ca2+ responses obtained in (A1 and B1) shows that the L-Lactate-induced potentiation also corresponds to 
an increase of the decay time (in comparison with the scaled Ca2+ response obtained in control, A2), with 
ryanodine blocking this effect on the Ca2+ response kinetics (B2). (C1,C2) Bar charts summarizing the effect of 
L-Lactate on the Ca2+ signal triggered by co-application of glutamate/glycine on untreated cultures (ncult = 11; 
ncells = 468; C1) or cultures pre-treated with ryanodine (ncult = 7; ncells = 331; C2). Note that, when cultures are 
pre-treated with ryanodine, the potentiating effect of L-Lactate significantly persists only for the amplitude of 
the Ca2+ signal. Results are presented as means ± SEM (*p < 0.05; ***p < 0.005; paired t-test).
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multi-modality imaging system combining Ca2+ imaging with Digital Holographic Microscopy (DHM), a tech-
nique that allows to detect early-stages of neuronal excito-toxic death14,33,34, we observed that 111 out of 135 cells 
(around 82%) displaying a transient Ca2+ response also exhibit a reversible decrease of the quantitative phase 
signal (QPS) (Δϕ = −22.5 ± 5.7°), this optical signal being synonymous with cell survival. In contrast 106 out 
of 128 cells (around 83%) displaying a sustained plateau of Ca2+ signal exhibit an irreversible decrease of QPS 
(Δϕ = −31.1 ± 7.4°), the latter being associated with the process of cell death14,33. This sustained plateau of the 
Ca2+ signal, which is a cell death marker, can be observed at a concentration of glutamate of 100 μM (p < 0.005) 
(Fig. 6B).
The cell death process is largely attributable to the activation of NR2B-containing NMDARs as the amplitude 
(0.57 ± 0.07 a.u) and the rate of cells displaying a sustained plateau of Ca2+ signal (9.7 ± 3.4%) are significantly 
decreased (<0.005 for the two parameters) by Ifenprodil (2 μM) (ncult = 6; ncells = 260) (Fig. 6C and Table 3). 
In the presence of L-Lactate (10 mM), the amplitude of the Ca2+ signals triggered by the mostly excito-toxic 
co-application of glycine/glutamate (1 mM/100 μM; 2 min) is equivalent to the control condition (0.88 ± 0.22 
a.u.; ncult = 8; ncells = 282) confirming that, for strong concentrations of glutamate, L-Lactate does not potenti-
ate the Ca2+ signal. However, under the same conditions, the percentage of cells displaying a sustained plateau 
for the Ca2+ signal is significantly decreased in the presence of L-Lactate (22.7 ± 3.7%; p < 0.005) (Fig. 6C and 
Table 3). Interestingly, this L-Lactate-induced neuroprotection pathway is mimicked by Pyruvate (9 ± 3.7% 
of cells displaying sustained plateau of Ca2+ signal; ncult = 6; ncells = 264) but not by D-Lactate (38.5 ± 7.4% of 
cells displaying sustained plateau of Ca2+ signal; ncult = 6; ncells = 246) (Fig. 6C and Table 3). Moreover, when 
Figure 5. The L-Lactate-induced potentiation is blunted at increased glutamate concentration; activation 
of a NR2B component in the calcium response appears. (A1a and A2a) Intracellular Ca2+ signals (black– and 
red-average Fura-2 ratio traces respectively for control condition and in presence of L-Lactate at 10 mM) 
recorded from 2 different cultures (A1a: ncell = 54; A2a: ncell = 29) and following 2 successive co-applications of 
glutamate/glycine (A1a: 10 μM/100 μM; A2a: 100 μM/100 μM; 2 min; dots). (A1b and A2b) Expanded calcium 
traces shown in A1a and A2a. In contrast to the Ca2+ response evoked by a weak glutamate concentration 
(Fig. 2), L-Lactate is inefficient at potentiating the Ca2+ response evoked by a strong concentration of glutamate. 
(A3) Bar charts summarizing the absence of potentiation by L-Lactate of Ca2+ responses evoked by the co-
application of glutamate/glycine when concentration of glutamate is 10 μM (ncult = 6; ncells = 276) or 100 μM 
(ncult = 6; ncells = 155). (B1a and B2a) Intracellular Ca2+ signals (black– and green-average Fura-2 ratio traces 
respectively for control condition and in presence of Ifenprodil at 2 μM) recorded from 2 different cultures (B1a: 
ncell = 31; B2a: ncell = 27) and following 2 successive co-applications of glutamate/glycine (B1a: 10 μM/100 μM; 
B2a: 100 μM/100 μM; 2 min; dots). (B1b and B2b) Expanded calcium traces shown in B1a and B1b. They clearly 
indicate a strong decrease of the Ca2+ response evoked by the co-application of glutamate/glycine in presence of 
Ifenprodil. (B3) Bar charts summarizing the significant blocking effect of Ifenprodil on Ca2+ responses evoked 
by the co-application of glutamate/glycine when concentration of glutamate is 10 μM (ncult = 6; ncells = 187) or 
100 μM (ncult = 6; ncells = 138). Results are presented as means ± SEM (***p < 0.001; paired t-test).
www.nature.com/scientificreports/
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pannexins are inactivated with carbenoxolone at 10 μM or ATP-sensitive potassium channels (KATP) with gliben-
clamide (200 μM), the L-Lactate-induced neuroprotection disappears with only 42.8 ± 3.5% (ncult = 5; ncells = 164) 
and 36 ± 4% (ncult = 4; ncells = 141) of cells displaying sustained plateau of Ca2+ signal respectively (Fig. 6C and 
Table 3). These results are in agreement with our recent study showing that the neuro-protective properties of 
L-Lactate against a glutamate excito-toxic insult are associated with a metabolic pathway linked to ATP produc-
tion, release and activation of a P2Y2/KATP cascade14. In contrast, the NADH pathway that mediates the potenti-
ating action of L-Lactate on low glutamate concentrations is not involved since the reducing agent DTT (1 mM) 
has no neuroprotective effect (54 ± 7.5% of cells displaying sustained plateau of Ca2+ signal; ncult = 6; ncells = 154) 
(Fig. 6C and Table 3).
Figure 6. L-Lactate decreases the rate of cell death triggered by excito-toxic concentration of glutamate. (A) Two 
representative reversible (A1) and non-reversible (A2) Ca2+ and QPS recorded from two different neurons after 
an excito-toxic co-application of glutamate/glycine (1 mM/100 μM; 2 min). (A1a and A2a) Fluorescence (top row) 
and QPS (below) images of neurons before (α & α′), 15 min after (β & β′) and 1 h after (γ & γ′) co-application of 
glutamate/glycine (Scale bar: 20 μm). The squares in the middle of cells correspond to the regions of interest where 
the fluorescent (Fura-2; Ratio) and QPS are measured. (A1b and A2b) Traces recorded in Fluorescence (red line) and 
in DHM (black line) from neurons in (A1a and A2a). For the neuron in A1, the fluorescent trace indicates a transient 
Ca2+ signal with a complete recovery concomitant to a reversible decrease of the QPS that are associated with 
recovery (non-cell death). In contrast, traces recorded in Fluorescence (red line) and in DHM (black line) from the 
neuron in A2a show a sustained Ca2+-plateau associated with an irreversible decrease of the QPS associated with a cell 
death process. (B) Bar charts summarizing the percentage of cells displaying a sustained Ca2+ -plateau for different 
concentrations of glutamate (1 μM: ncult = 9; ncells = 275; 10 μM: ncult = 6; ncells = 276; 100 μM: ncult = 6; ncells = 155; 
1 mM: ncult = 7; ncells = 263). This difference becomes significant for glutamate concentrations from 100 μM. (C) The 
bar chart shows the percentage of glutamate/glycine-induced Ca2+ sustained plateau obtained in different conditions: 
control (ncult = 7; ncells = 263), Ifenprodil (2 μM; ncult = 6; ncells = 260), L-Lactate (10 mM; ncult = 8; ncells = 282), Pyruvate 
(10 mM; ncult = 6; ncells = 264), D-Lactate (10 mM; ncult = 6; ncells = 246), L-Lactate (10 mM) + Carbenoxolone (10 μM) 
(ncult = 5; ncells = 164), L-Lactate (10 mM) + glibenclamide (200 μM) (ncult = 4; ncells = 141) and DTT (1 mM; ncult = 6; 
ncells = 154). Only L-Lactate, Pyruvate and Ifenprodil significantly decrease the percentage of cells displaying a 
sustained Ca2+-plateau. Results are presented as means ± SEM (***p < 0.005, One-way Anova/post-test “Dunnett’s” ).
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Discussion
In recent years two apparently contrasting effects of L-Lactate have been demonstrated: the potentiation of the 
NMDAR activity resulting in plasticity gene expression6 and the neuroprotective effect against excessive NMDAR 
activity14, the question being then how the same molecule can potentiate some positive effects of glutamate while 
inhibiting others, both involving NMDARs? In this report, we show that this apparent paradox is explained 
by the efficiency of L-Lactate to potentiate NMDARs for a certain activation window corresponding to a sub-
threshold concentration of glutamate. Indeed, the data reported here clearly show that L-Lactate potentiates the 
NMDAR activity only for 1 μM of glutamate, a concentration in the range of its EC50 for NMDARs (around 
0.5–5 μM). In contrast, the L-Lactate-induced potentiation disappears for concentrations ranging between 10 μM 
to 1 mM of glutamate, thus excluding any direct role of L-Lactate in the excessive activation of NMDARs during 
an excito-toxic episode. This “activity switch” of L-Lactate results in its neuroprotective properties to significantly 
decrease the cell death process against an exposure to high concentrations of glutamate (and glycine) through a 
complex metabolic pathway involving the synthesis of Pyruvate, ATP release (through the opening of pannex-
ins) and subsequent activation of the ATP-dependent potassium channel KATP as shown previously14. The only 
common point between the potentiation and neuroprotective pathways is L-Lactate itself while the two products 
resulting from its metabolism namely NADH and ATP, are involved in potentiation (NADH) and in neuropro-
tection (ATP) (Fig. 7). Most importantly, there is no interconnection between these two pathways as revealed by 
the fact that:
 1. Pyruvate is neuroprotective but unable to potentiate NMDAR activity, in fact decreasing it, probably 
because it decreases the neuronal excitability through the final activation of KATP channels14. Indeed, as 
NMDARs are open under a depolarized membrane potential, activation of KATP channels will result in a 
decrease of excitability counteracting NMDAR activation. This mechanism also explains why Pyruvate 
decreases the Ca2+ signal evoked by a low concentration of glutamate. A notable point concerns D-Lactate 
which also decreases the Ca2+ signal potentiated by L-Lactate in the presence of low concentrations of 
glutamate. Indeed, D-Lactate is a non-metabolizable analogue of L-Lactate without apparent action on the 
KATP, unlike Pyruvate14. However, D-Lactate has been shown to strongly reduce neuronal activity by acting 
on the G-protein-coupled Lactate receptors, GPR81 (HCA1)35 which in turn decreases the excitability of 
the neuronal network and, by consequence, the probability to activate NMDARs by a subliminal concen-
tration of glutamate. However, in contrast to Pyruvate, D-Lactate is not efficient to protect neurons against 
excito-toxic insults in vitro14.
 2. The reducing agent DTT which presumably mimics the effect of NADH, by affecting redox-sensitive 
processes, potentiates NMDAR activity without neuroprotective properties, a result in agreement with 
literature since the reduced state of NMDARs stimulates its own activity16,17, in particular evoked by 
DTT18,36. Here it should be noted that the potentiation of Ca2+ signal induced by L-Lactate is slightly lower 
than the DTT-induced potentiation (+52% vs +69%), a result consistent with the fact that the pure poten-
tiation activity of L-Lactate is partly counteracted by its involvement in the Pyruvate pathway (decrease of 
membrane excitability).
Our results clearly show that extracellular application of L-Lactate produces an increase of the intracellu-
lar NADH/NAD+ ratio confirming the relationship between the cytosolic NADH production originating from 
Glutamate/Glycine (1 mM/100 μM; 2 min)





(ncult = 7; ncells = 263)
51.4 ± 6.7
Ifenprodil (2 μM)
(ncult = 6; ncells = 260)
9.7 ± 3.4 <0.005
L-Lactate (2 mM)
(ncult = 6; ncells = 338)
42.6 ± 7.8 n.s
L-Lactate (5 mM)
(ncult = 6; ncells = 302)
28.7 ± 4.9 <0.05
L-Lactate (10 mM)
(ncult = 8; ncells = 282)
22.7 ± 3.7 <0.005
Pyruvate (10 mM)
(ncult = 6; ncells = 264)
9.0 ± 3.7 <0.005
D-Lactate (10 mM)
(ncult = 6; ncells = 246)
38.5 ± 7.4 n.s
L-Lactate (10 mM) + carbenoxolone
(10 μM) (ncult = 5; ncells = 164)
42.8 ± 3.5 n.s
L-Lactate (10 mM) + glibenclamide
(200 μM) (ncult = 4; ncells = 141)
36.0 ± 4.0 n.s
DTT (1 mM)
(ncult = 6; ncells = 154)
54.0 ± 7.5 n.s
Table 3. Summary of the rate of sustained plateau of Ca2+ signal (cell death process) induced by glutamate in 
different conditions. Values are means ± SEM. Statistics data correspond to a Dunnett’s post hoc test following a 
one-way ANOVA (n.s: non significant, p > 0.05).
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L-Lactate metabolism and L-Lactate-induced NMDAR potentiation of the Ca2+ signal. In contrast, the 5 mM 
extra Glucose ACSF has no effect on the intracellular NADH/NAD+ ratio and, in parallel, decreases the Ca2+ 
signal induced by the glutamate/glycine cocktail. Such a result is consistent with the work of Porras et al.37 show-
ing that glutamate does not trigger Glucose utilization but rather inhibits Glucose transport and utilization in 
neurons. In contrast, other studies showed that neuronal depolarization is accompanied by an increase in cyto-
solic NADH/NAD+ ratio that is associated with a reduction of the malate-aspartate shuttle activity through the 
glycolytic pathway38. It was also observed that Glucose utilization is positively correlated with intracellular Ca2+ 
signaling whereas L-Lactate utilization is not24,39. Our observation that the inhibition of LDH by stiripentol is 
sufficient to block the L-Lactate-induced potentiation does not argue in favor of a role of the modulation of 
malate-aspartate shuttle as source of NADH in the potentiation of Ca2+ signal associated to NMDAR activity. 
Moreover, this Glucose-induced Ca2+ signaling seems to be effective for 100–300 μM of NMDA39,40. This range of 
NMDA concentrations being 4 to 10 fold higher than the EC50 for NMDARs expressing the NR2B sub-unit41, it is 
conceivable that, at 100–300 μM of NMDA, all of NR2B-containing NMDARs are activated by these high concen-
trations of NMDA, a situation that does not require L-Lactate which is only active on “silent” NR2B-containing 
NMDARs. Besides, our results clearly show that, at high concentrations of glutamate (or NMDA), L-Lactate 
would tend to decrease the amplitude of the Ca2+ signal which may explain why Glucose (and not L-Lactate) is 
positively correlated with intracellular Ca2+ signaling when NMDA is around 100–300 μM24,39. In conclusion, 
while we cannot exclude glycolysis (i.e. Glucose metabolism) and the malate-aspartate shuttle as possible met-
abolic pathways related to intracellular NADH production in neurons, our results demonstrate that L-Lactate 
metabolism (through LDH activity) is the main pathway involved in the production of cytosolic NADH allowing 
the potentiation of Ca2+ signal associated with NMDAR activity.
Concerning more specifically the redox state of the cell, the presence of redox sites located on the extra-
cellular part of NMDARs on the NR1 subunit has been demonstrated17. We have observed that bath applica-
tion of DTT, a reducing agent, induces a potentiation of NMDAR activity suggesting a possible extracellular 
action of this agent. Furthermore, bath application of DTNB, an oxidizing agent considered as membrane imper-
meant42, blocks the L-Lactate-induced potentiation strengthening the view that extracellular redox-sensitive sites 
on NMDARs are being affected. Of note is the fact that the L-Lactate-induced potentiation is also blocked by 
stiripentol, an inhibitor of the intracellular enzyme LDH involved in the conversion of Lactate to Pyruvate and, 
by consequence, in the regulation of the intracellular NADH/NAD+ ratio. This consideration would indicate 
that the changes in redox state evoked by the changes in the NADH/NAD+ ratio are likely to operate intracel-
lularly as a primary site of action. However, extracellular sites of action of intracellular-produced NADH acting 
Figure 7. Schematic representation of the dual effect of L-Lactate. Extracellular L-Lactate is transported 
into neurons (1) and is metabolized by Lactate Dehydrogenase (LDH) in presence of NAD+ (2) to produce 
Pyruvate and NADH. Pyruvate and NADH are engaged in two distinct and independent pathways: Potentiation 
Pathway (or NADH Pathway in red): For a subthreshold concentration of glutamate unable to activate 
NR2B-containing NMDARs, NADH acts as reducing agent (3) to allow the opening of the NR2B-containing 
NMDARs’ ion channel resulting in a Ca2+ influx (4). Neuroprotective Pathway (or Pyruvate/ATP Pathway in 
green): When glutamate over-activity triggers a strong inflow of Ca2+ through the NR2B-containing NMDARs, 
Pyruvate is metabolized into the mitochondria to produce ATP then released through pannexins (5) to act 
on the metabotropic purinergic receptor P2Y2 in an autocrine/paracine manner (6). Stimulation of P2Y2 
receptors activates the PI3K pathway (7) which, in turn, elicits the opening of KATP channels, hence leading 
to hyperpolarization of neurons (8), the consequence being a decrease in neuronal excitability leading to 
neuroprotection (decrease of the Ca2+ influx through the closure of NMDARs) (9). Points 6 and 7 have been 
presented in Jourdain et al.14.
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on extracellular redox-sensitive NMDAR sites could be considered. Indeed, it has been suggested that NADH 
(and NAD+) can be transported across the plasma membrane43 via the purinergic P2X7 receptor44, a receptor 
also expressed in neurons45,46. Thus it is conceivable that intracellularly formed NADH is released through P2X7 
receptors and acts on extracellular redox-sensitive sites of the NMDAR. Further work will be needed to confirm 
or invalidate this hypothesis. Another additional mechanism of red/ox-dependent NMDAR activity modulation 
by L-Lactate is related to the intracellular RyRs known to be involved in the release of Ca2+ from intracellular 
stores, which expresses a few cysteine residues highly susceptible to oxidative modifications28. Nevertheless, the 
fact that L-Lactate-induced NMDAR-dependent potentiation of the Ca2+ peak amplitude persists despite the 
blockade of RyRs provides evidence that RyRs are not the main target of the redox change initiated by L-Lactate. 
Nevertheless, our results confirm that RyRs contribute to the maintenance of the Ca2+ influx generated by 
NMDAR activation25,26.
An additional question concerns the nature of NR2 subunit expressed in NMDARs which is potentiated 
by L-Lactate. Our data show that, in control conditions, the Ca2+ signal evoked by a low concentration of glu-
tamate (1 μM), in association with a saturating concentration of glycine (100 μM), is not due to activation of 
NR2B-containing NMDARs since Ifenprodil, the specific blocker of the NR2B sub-unit, is ineffective in blocking 
this Ca2+ signal. Since NR2A and NR2B subunits are more strongly expressed than NR2C and NR2D subunits 
in cortical neuronal cultures47 it is likely that the Ca2+ signal evoked in control conditions is mainly due to an 
activation of NR2A-containing NMDARs. In the presence of L-Lactate, an additional Ca2+ component appears. 
Indeed, as shown in Fig. 2A, this additional Ca2+ component is associated with an activation of NR2B-containing 
NMDARs since not only it is blocked by Ifenprodil but also L-Lactate is less efficient at potentiating the evoked 
Ca2+ signal when glutamate is co-applied with D-Serine, the analogue of glycine purported to be more specific 
to the NR2A sub-unit23. Moreover, we still observe this L-Lactate-induced potentiation when we substitute 1 μM 
glutamate with 30 μM of NMDA, this NMDA concentration corresponding to its EC50 for NMDARs expressing 
the NR2B sub-unit41. Finally, the additional Ca2+ component induced by DTT is also sensitive to Ifenprodil, a 
result in agreement with the fact that NR2B subunit has an additional redox site involving a more long-lasting 
effect of reducing agents for NR1/NR2B than for NR1/NR2A48.
We cannot exclude a possible potentiating action of L-Lactate on NR2A-containing NMDARs. However 
the location of these NR2A-containing NMDARs, essentially in postsynaptic membrane49, implies that they are 
exposed to high (saturating) concentrations of glutamate in the synaptic cleft during an excitatory stimulus, up 
to 1 mM during an action potential50. In contrast, the NMDARs expressing the NR2B sub-unit are thought to 
be localized pre- or extra-synaptically51,52. Reported values of baseline glutamate concentrations in extracellular 
space at these sites range between 0.02 to 5 μm in vitro or in vivo21,53. Furthermore these concentrations remain 
relatively stable because of the rapid uptake of glutamate by astrocytic glutamate transporters even during high 
frequency stimulation54,55. Finally, reports have shown that NR2B-containing NMDARs are associated with adja-
cent astrocytic processes56, allowing for modulation of synaptic activity56,57 and enabling the synchronization of 
neural networks through the genesis of large Slow Inward Currents58,59.
It has also been shown recently that NR2B-containing NMDARs are necessary for the formation of Long 
Term Potentiation60. This observation, taken with the demonstration that L-Lactate transport from astrocytes 
to neurons is necessary for LTP and memory consolidation9 raises some heuristically interesting considerations. 
The observation that L-Lactate potentiates NMDAR activity as shown in the present article concerning Ca2+ 
signaling and in Yang et al.6 concerning the induction of plasticity genes should be placed in the context of in 
vivo studies showing that L-lactate produced from astrocytic glycogen is necessary for memory consolidation9,10. 
Indeed glycogenolysis in astrocytes resulting in L-Lactate formation61 is dependent on beta2-adrenergic receptor 
activation10. The release of L-Lactate and its uptake into neurons via MCT2 transporters promotes plasticity genes 
expression and is necessary for memory consolidation. One of the behavioral modalities during which the Locus 
Coeruleus, the main source of noradrenergic fibers projecting to the hippocampus and neocortex, is the atten-
tional regime that accompanies learning62. Thus, the behavioral modality that would result in the potentiation 
of NMDAR signaling by L-lactate would indeed be the attention- and learning-mediated release of the glycog-
enolytic neuromodulator noradrenaline onto glycogen-containing astrocytes in the cortex. It is thus reasonable 
to hypothesize that an astrocytic release of L-Lactate after a noradrenergic stimulation can activate some pre- or 
extra-synaptic NR2B-containing NMDARs which are normally “silent” because the ambient concentration of glu-
tamate is very low (<1 μM). In turn, the activation of such pre- or extra-synaptic NR2B-containing NMDARs can 
modulate the threshold of the induction of Long Term Potentiation. Such a sequence of events is consistent with 
the modulatory role of L-Lactate on neuronal plasticity and Long-Term Memory formation9. Because of its slower 
kinetics causing stronger Ca2+ influx51, the NR2B sub-unit is also involved in extra-synaptic NMDAR-dependent 
death signaling63 consistent with our results showing that Ifenprodil strongly and significantly decreases the rate 
of cell death induced by an excito-toxic application of glutamate.
Finally, this dual action of L-Lactate on the activity of NR2B-containing NMDARs is also dependent on the 
extracellular L-Lactate concentration. The fact that the efficient concentrations of L-Lactate are different for 
potentiation and/or neuroprotection (Tables 1 and 3) reinforces the notion of two independent pathways for 
L-Lactate. As it is the case for glutamate whose concentration may range between 1 μM and 1 mM, notably in the 
synaptic cleft during neuronal activation21, it is likely that L-Lactate can also reach high concentrations locally. 
Indeed, considering a width of the extracellular space between neurons and astrocytes ranging from 50 nm to 
3.2 µm64 and the fact, that the astrocytic release of L-Lactate is faster (>105 Lactate molecules per second) than the 
slow L-Lactate re-uptake by the neuronal MCTs (around 102 Lactate molecules per second)65 it is likely that the 
extracellular L-Lactate concentrations can locally reach concentrations of 10 mM and even higher in the vicinity 
of the synapse.
In conclusion, as summarized in Fig. 7, the present results demonstrate the dual and at first analysis para-
doxical properties of L-Lactate to potentiate and to protect respectively neuronal networks. The occurrence of 
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each effect is dependent on the strength of the glutamatergic stimulus to activate (or not) pre- or extra-synaptic 
NR2B-containing NMDARs. To our knowledge, there are no or few molecules with these dual properties which 
make L-Lactate a potentially attractive candidate for clinical and pharmacological research in particular for nerv-
ous system pathologies such as stroke, spinal cord injury and progressive neurodegenerative diseases.
Materials and Methods
Experiments were conducted in accordance with the Swiss Federal Guidelines for Animal Experimentation and 
were approved by the Cantonal Veterinary Office for Animal Experimentation (Vaud, Switzerland).
Cell culture preparation. Primary cultures of cortical neurons were prepared from embryonic day 17 (E17) 
OF1 mice embryos (Charles River Laboratories, L’Arbresle, France) as previously described6. Neurons were plated 
on 25 mM poly-L-Ornithine (Sigma) coated coverslips at an average density of 4 × 104 cells/cm2 and maintained 
in Neurobasal medium (Gibco, containing 25 mM Glucose) supplemented with B27 (Gibco), GlutaMAX, penicil-
lin (50 U/mL) and streptomycin (50 µg/mL) (Invitrogen, Basel, Switzerland) at 37 °C in a humidified atmosphere 
containing 5% CO2 and 95% air and were used at day in vitro (DIV) 17 to 22. These culture conditions typically 
produced 93% pure neuronal cultures, as assessed by microtubule-associated protein 2 (MAP2, neuronal marker) 
and glial fibrillary acidic protein (GFAP, astrocytic marker) co-immunostaining66.
Cell loading. Cells are loaded with Fura-2-AM (Fura-2, Invitrogen) in order to measure intracellular [Ca2+]. 
Fura-2 is diluted in DMSO at stock concentrations of 2 mM. 2 μl of this stock are then added to 1 ml of perfusion 
medium with 1% Bovine Serum Albumine (BSA, Sigma) added to improve uptake of the dye. Cells were loaded in 
this solution for 30 minutes at 37 °C. For experiments with Ryanodine (Tocris), the blocker is added to the loading 
solution at 100 μM during 30 minutes. In these conditions, the effect of Ryanodine is irreversible29.
Optical set-up. Microscopy was performed on a DHM T1000 microscope (Lyncée Tec SA) with an added 
custom fluorescence module67. The DHM component of the measurement system consists in a standard transmis-
sion DHM setup68,69 enabling the monitoring of cells in time through phase measurement as described in other 
studies33,67. In short, the light emitted by a laser diode (λ = 684 nm), is split into two beams: The object beam 
interacts with the specimen, and the scattered light is collected by a 10x microscope objective having a numerical 
aperture of 0.3 in air (Leica Microsystems, Fluotar). This beam forms an interference pattern with the reference 
beam which is recorded by a CCD camera (8-bit, pixel size 6.45 μm) in the Fresnel regime. Briefly, quantitative 
phase signals (QPS) using QP-DHM is an interferometric imaging technique that allows to visualize69 transparent 
specimens, including living cells, by measuring the phase retardation induced by the specimens on a transmitted 
wave (for a more detailed description of the basic design of the imaging system, see Marquet et al.69). In the con-
text of living cells recordings by QP-DHM, the phase retardation or QPS, expressed as Δϕ, is highly sensitive to 
the intracellular refractive index, which mainly depends on protein content70. Consequently, any transmembrane 
water movement, modifying the intracellular refractive index through a dilution or concentration process, dras-
tically alters the QPS70. Therefore, a decrease of QPS corresponds to an inflow of water while an increase of phase 
shift indicates an exit of water33,70.
The fluorescence excitation light is provided by a monochromator (Polychrome V, Till Photonics), delivering 
light ranging from 320 nm to 680 nm, with a power of typically 10 mW at 470 nm and a bandwidth of 15 nm. 
Employing a monochromator enables the possibility of rapidly switching the excitation wavelength without 
using any excitation filter, thus avoiding any mechanical movement. The ratiometric dye Fura-2 is excited at both 
λ1 = 340 nm and λ2 = 380 nm. In order to enable excitation for Fura-2, a dichroic mirror with a cutting wave-
length of 409 nm is used to send the excitation light to the specimen, while the fluorescence emission is filtered 
at 510 nm with 84 nm bandwidth. The fluorescence light is then detected by a CCD camera (INFINITY3S-1, 
Lumenera Corporation) recording 16-bit images with an exposure time of 800 ms.
The extraction of the two different signals of fluorescence and DHM was performed by employing two dif-
ferent dichroic mirrors, enabling first the separation of the line wavelength employed for digital holography, and 
second to enable the epifluorescence excitation67.
Fluorescence measurements. Fluorescence images are acquired with the Micro-Manager software (as 
described in Edelstein et al.71), at a frame rate of 0.15 Hz. Temporal signals are then extracted from images by 
computing the mean value of the fluorescence intensity within the cell soma. A baseline, measured as the average 
signal of 5 empty regions in the field of view, is then subtracted from all signals to suppress the background con-
tribution. Signals from Fura-2 are then computed as ratios R of the two excitation wavelengths (F340/F380).
Phase signal measurements. Holograms are acquired at a frame rate of 0.1 Hz during all experiments. 
Quantitative phase images are then retrieved from measured holograms by employing standard reconstruction 
methods for off-axis holograms68,72 as provided by the Koala software (Lyncée Tec SA). Temporal phase signals 
are then extracted from images by monitoring the mean phase value within the cell soma, where a background 
signal is also subtracted from an empty region in the field of view to suppress potential drifts in the signal. An 
extensive quality control of the DHM technique has been published by Rappaz et al.73.
Experimental protocol. Coverslips were mounted on a closed perfusion chamber used to apply differ-
ent media to the cells. Standard media (ACSF) consisted of HEPES-buffered standard physiological perfusion 
medium14 and containing NaCl 140 mM, KCl 3 mM, CaCl2 3 mM, MgCl2 2 mM, Glucose 5 mM, HEPES 10 mM, 
adjusted to a pH of 7.3 with NaOH.
All experiments were performed at room temperature. Glutamate, Glycine, D-Serine, L-Lactate, D-Lactate, 
Pyruvate, MK801, Ifenprodil, dithiothreitol (DTT), 5,5′-dithiobis(2-nitrobenzoic acid) (DTNB), Stiripentol 
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were provided by Sigma-Aldrich and added to ACSF. For most experiments, 2 successive pulses of glutamate 
(1–100 μM) and glycine (100 μM) are applied to the cells spaced out by a minimum delay of 20 min. The ampli-
tude of the 1st and the 2nd Ca2+ response induced by the glutamate/glycine cocktail are compared. For the exper-
iments performed at 1 mM of glutamate (+100 μM of glycine), only a single pulse is applied due to a higher 
number of excito-toxic responses. Finally, for some experiments, 5 mM of Glucose are added to the ACSF (final 
concentration of Glucose: 10 mM; annotated 5 mM extra Glucose ACSF).
NADH/NAD+ assay. Cycling assays for nicotinamide adenine dinucleotides were adapted from previously 
published methods74,75. Cells were pre-incubated in ACSF during 30 min at 37 °C and subsequently switched 
to normal ACSF (control), L-Lactate-containing ACSF or 5 mM extra Glucose ACSF for an extra 10 min at 
37 °C. Then cells were rinsed twice with ice-cold PBS, harvested in 400 μL ice-cold carbonate-bicarbonate buffer 
(100 mM Na2CO3, 20 mM NaHCO3 containing 10 mM Nicotinamide to inhibit NADase), and frozen at −80 °C. 
Cell membranes were lysed by heat-shock in a 37 °C water bath and immediately chilled on ice. Extracts were 
centrifuged at 12,000 × g for 30 min at 4 °C and half of the supernatant was heated at 60 °C for 30 min to dena-
ture NAD. 100 μL of the heated extract (containing NADH only), 25 μL of the unheated extract (containing 
NAD and NADH) and 50 µL of standards of known NADH (Roche) concentrations (ranging from 0.0625 to 
1 µM) dissolved in carbonate-bicarbonate buffer were loaded in duplicate onto a 96-well microplate along with 
blanks (carbonate-bicarbonate buffer). Volumes were adjusted to 100 µL with carbonate-bicarbonate buffer and 
150 μL of a reaction buffer was added into each well. Reaction buffer contained Bicine 133 mM, EDTA 5.33 mM, 
Methylthiazolyldiphenyl-tetrazolium bromide (MTT) 0.56 mM, Phenazine Ethosulfate (PES) 2.21 mM, Ethanol 
0.67 M, and Alcohol Dehydrogenase (Sigma-Aldrich) 40 U/mL. The absorbance was followed spectrophotomet-
rically at 560 nm every 15 s over a 15 min period (Safire 2; Tecan, Maennedorf, Switzerland). Blank values were 
subtracted from all samples and NAD amounts were calculated by subtracting NADH values from total NAD+ 
NADH concentrations. The protein content was measured using the remaining cell lysate using the BCA pro-
tein assay reagent kit (Pierce) according to the manufacturer’s instructions and used for normalization. Ratio of 
NADH/NAD+ values are expressed as percentage of control values (NADH/NAD+ of 6.49 +/− 0.65 with basal 
NADH cellular content of 205.15 ± 23.84 pmol/mg prot).
Statistical analysis. A minimum of 20 neurons per culture were analyzed for each experiment. All data are 
presented as means ± SEM. Paired Student’s t-test or One-way ANOVA followed by Dunnett’s post hoc test have 
been used to determine statistical significance (*p < 0.05; **p < 0.01; ***p < 0.005).
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